Excited to present data from TROPHY-U01, cohort 3 (phase 2 trial): SG + pembro looks very promising in advanced platinum-refractory urothelial Ca & met the primary endpoint: ORR 41%, CR 20%, 72% reduction in tumor size, mDOR 11 mo, median time to response 1.4 mo, median PFS 5.3 mo, median OS 12.7 months; toxicity as expected with either agent alone (neutropenia & diarrhea need close attention): role of a phase 3 trial?
The numbers are in, and the cloud infrastructure market grew at a brisk pace this quarter driven by increasing interest in generative AI.
This analysis indicates that quantitative interstitial abnormalities may indicate alterations in lung tissue processes that can result in short- and long-term consequences as far as…
Days after they were born, Eli and Easton Reed were diagnosed with spinal muscular atrophy.
If you’ve missed a birth control pill, you may be worried about what to do next. An Ob/Gyn explains the different scenarios and what kind…
ACC President Cathie Biga, MSN, FACC launched her “Heart Talk with Cathie” presidential discussion live from MedAxiom’s CVTransforum in Atlanta. With the hel…
Artificial intelligence has become a transformational force in healthcare, bolstering medical research, care delivery and health system operations.
Plastic changes in the brain are primarily limited to early postnatal periods. Recovery of adult brain plasticity is critical for the effective development of therapies.…
Chromoplexy is detectable using targeted NGS in a substantial portion of EWSR1-rearranged round cell sarcomas as an early and persistent clonal event, expanding the genomic…
